Finland· FI-REL-REL55559
Juluca
A dolutegravir and rilpivirine product containing dolutegravir sodium + rilpivirine hydrochloride, registered in Finland by Orifarm Oy. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Dolutegravir and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR21 (dolutegravir and rilpivirine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Dolutegravir and rilpivirine · ATC J05AR21
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Dolutegravir sodium + Rilpivirine hydrochloride
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- J05AR21
- ATC class
- Dolutegravir and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa49625430EUR 739.74
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dolutegravir and rilpivirine in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJULUCAViiV Healthcare BV, Amersfoort
- United StatesJulucaViiV Healthcare Company
- FranceJULUCA 50 mg/25 mg, comprimé pelliculéVIIV HEALTHCARE (PAYS-BAS)
- CanadaJULUCAVIIV HEALTHCARE ULC
- IcelandJulucaViiV Healthcare BV
- NetherlandsJuluca 50 mg/25 mg, filmomhulde tablettenViiV healthcare B.V.
- NorwayJulucaViiV Healthcare BV (1)
- PolandJulucaViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Juluca
- Liechtenstein · Juluca
- Norway · Juluca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af5ccd0b-e408-495f-949c-e9c36f05b4d2 GET /v1/drugs/af5ccd0b-e408-495f-949c-e9c36f05b4d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "1",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "ED",
"strength": "50 mg / 25 mg",
"atc_label": "dolutegraviiri ja rilpiviriini",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/18/1282/001",
"fimea_rel_id": "REL55559",
"authorised_at": "2019-10-18"
}See everything about dolutegravir and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.